Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 2173 Salk Ave Ste 200 CARLSBAD CA 92008-7354 |
Tel: | N/A |
Website: | https://lineagecell.com |
IR: | See website |
Key People | ||
Brian M. Culley Chief Executive Officer, Director | Jill Howe Chief Financial Officer | Gary S. Hogge Senior Vice President - Clinical and Medical Affairs | George A. Samuel General Counsel, Corporate Secretary |
Business Overview |
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company's programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1. |
Financial Overview |
For the fiscal year ended 31 December 2023, Lineage Cell Therapeutics Inc revenues decreased 39% to $8.9M. Net loss decreased 18% to $21.5M. Revenues reflect Collaboration revenues decrease of 43% to $7.6M. Lower net loss reflects Other General and administrative decrease of 29% to $13.5M (expense), Other income(expense), net decrease of 100% to $4K (expense), Unrealized marketable securities decrease of 92% to $176K (expense). |
Employees: | 75 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $172.04M as of Dec 31, 2023 |
Annual revenue (TTM): | $8.95M as of Dec 31, 2023 |
EBITDA (TTM): | -$24.04M as of Dec 31, 2023 |
Net annual income (TTM): | -$21.49M as of Dec 31, 2023 |
Free cash flow (TTM): | -$29.24M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 188,533,536 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |